Celsus Therapeutics Plc. (CLTX) 4.70 $CLTX
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 104.59 (+0.31), RVNC: 16.65 (+0.42), CLTX: 4.70 (-0.20), GSK: 42.85 (+0.11), NKTR: 15.02 (+0.23), NVS: 93.91 (+0.66)
Celsus Therapeutics Announces Upcoming Presentation at Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Tue Dec 02, 6:30AM CST
Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announces that Gur Roshwalb, MD, chief executive officer, is scheduled to present at the Oppenheimer 25 Annual Healthcare Conference at Crowne Plaza Hotel in New York City. Dr. Roshwalb will provide a corporate overview and update and will be available to conduct one-on-one meetings with investors.
CLTX: 4.70 (-0.20)
Falling Earnings Estimates Signal Weakness Ahead for InnerWorkings (INWK) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:50AM CST
InnerWorkings (INWK) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions over the last month as well.
ASGN: 33.66 (+0.33), CTP: 14.57 (-0.18), CLTX: 4.70 (-0.20), INWK: 7.82 (-0.04)
Global Contact Dermatitis Therapeutics Pipeline Review 2014 - Analysis of 4 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/bdskj2/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Contact Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - R-Tech Ueno, Ltd. - Marinomed Biotechnologie GmbH - Anacor Pharmaceuticals, Inc. - Celsus Therapeutics Plc Drug Profiles - MRX-6 - RTU-1096 - bordetella pertussis vaccine [BPZE1] - MAM-06301 - AN-3485 - HPT-721 For more information visit http://www.researchandmarkets.com/research/bdskj2/contact
CLTX: 4.70 (-0.20), ANAC: 30.58 (+0.16)
Celsus Therapeutics Plc Announces First Patient Enrolled in Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis
GlobeNewswire - Wed Aug 06, 6:30AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
CLTX: 4.70 (-0.20)
Celsus Therapeutics Plc Receives Approval From the Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients
GlobeNewswire - Tue Jun 17, 6:10AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
CLTX: 4.70 (-0.20)
Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ
GlobeNewswire - Thu Jan 30, 4:32PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing of its public offering of 1,333,333 American Depository Shares ("ADSs"
on the NASDAQ Capital Market at a price of $6.00 per ADS. Each ADS represents ten of the Company's ordinary shares. The gross proceeds from this offering, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $8,000,000. The offering is expected to close on or about February 5th, 2014, subject to customary closing conditions. Celsus also granted the underwriter a 30-day option to purchase 200,000 additional ADSs at the public offering price to cover over-allotments, if any.
CLTX: 4.70 (-0.20)
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 104.59 (+0.31), RVNC: 16.65 (+0.42), CLTX: 4.70 (-0.20), GSK: 42.85 (+0.11), NKTR: 15.02 (+0.23), NVS: 93.91 (+0.66)
Celsus Therapeutics Announces Upcoming Presentation at Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Tue Dec 02, 6:30AM CST
Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announces that Gur Roshwalb, MD, chief executive officer, is scheduled to present at the Oppenheimer 25 Annual Healthcare Conference at Crowne Plaza Hotel in New York City. Dr. Roshwalb will provide a corporate overview and update and will be available to conduct one-on-one meetings with investors.
CLTX: 4.70 (-0.20)
Falling Earnings Estimates Signal Weakness Ahead for InnerWorkings (INWK) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:50AM CST
InnerWorkings (INWK) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions over the last month as well.
ASGN: 33.66 (+0.33), CTP: 14.57 (-0.18), CLTX: 4.70 (-0.20), INWK: 7.82 (-0.04)
Global Contact Dermatitis Therapeutics Pipeline Review 2014 - Analysis of 4 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/bdskj2/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Contact Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - R-Tech Ueno, Ltd. - Marinomed Biotechnologie GmbH - Anacor Pharmaceuticals, Inc. - Celsus Therapeutics Plc Drug Profiles - MRX-6 - RTU-1096 - bordetella pertussis vaccine [BPZE1] - MAM-06301 - AN-3485 - HPT-721 For more information visit http://www.researchandmarkets.com/research/bdskj2/contact
CLTX: 4.70 (-0.20), ANAC: 30.58 (+0.16)
Celsus Therapeutics Plc Announces First Patient Enrolled in Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis
GlobeNewswire - Wed Aug 06, 6:30AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
CLTX: 4.70 (-0.20)
Celsus Therapeutics Plc Receives Approval From the Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients
GlobeNewswire - Tue Jun 17, 6:10AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
CLTX: 4.70 (-0.20)
Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ
GlobeNewswire - Thu Jan 30, 4:32PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing of its public offering of 1,333,333 American Depository Shares ("ADSs"
on the NASDAQ Capital Market at a price of $6.00 per ADS. Each ADS represents ten of the Company's ordinary shares. The gross proceeds from this offering, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $8,000,000. The offering is expected to close on or about February 5th, 2014, subject to customary closing conditions. Celsus also granted the underwriter a 30-day option to purchase 200,000 additional ADSs at the public offering price to cover over-allotments, if any. CLTX: 4.70 (-0.20)
